Detalles de la búsqueda
1.
ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer.
Cancer Sci
; 111(3): 962-973, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31960523
2.
mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
Int J Clin Oncol
; 24(5): 516-525, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30612267
3.
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
N Engl J Med
; 372(20): 1909-19, 2015 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-25970050
4.
Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker.
BMC Cancer
; 18(1): 406, 2018 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29642865
5.
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
BMC Cancer
; 17(1): 38, 2017 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28068936
6.
RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
Int J Cancer
; 139(4): 803-11, 2016 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27004837
7.
Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
Invest New Drugs
; 34(4): 468-73, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27155613
8.
Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
Gastric Cancer
; 19(2): 625-630, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26260873
9.
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Int J Clin Oncol
; 21(4): 696-703, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26710796
10.
A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
Ann Surg Oncol
; 22(3): 908-15, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25465375
11.
Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
BMC Cancer
; 15: 760, 2015 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-26490659
12.
Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
BMC Cancer
; 15: 176, 2015 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-25884814
13.
Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy.
Ann Pharmacother
; 49(10): 1120-4, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26160973
14.
[Three cases of fatal thrombocytopenia after oxaliplatin-based chemotherapy].
Gan To Kagaku Ryoho
; 40(11): 1557-60, 2013 Nov.
Artículo
en Japonés
| MEDLINE | ID: mdl-24231715
15.
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Lancet Oncol
; 13(10): 993-1001, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22951287
16.
A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer.
Invest New Drugs
; 30(5): 2026-31, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22160802
17.
Clinical outcome of biliary drainage for obstructive jaundice caused by colorectal and gastric cancers.
Jpn J Clin Oncol
; 42(12): 1161-7, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23072841
18.
[A case of transverse colon cancer with multiple liver metastases and hepatic pedicle lymph node involvement showing pathological complete response by XELOX plus bevacizumab].
Gan To Kagaku Ryoho
; 39(13): 2561-3, 2012 Dec.
Artículo
en Japonés
| MEDLINE | ID: mdl-23235180
19.
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.
Cancer Sci
; 102(6): 1188-92, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21401804
20.
Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
Cancer
; 117(17): 4026-32, 2011 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21858803